ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025
Remodeling the Physicochemical and Pharmacokinetic Properties of PROTAC via Lipid Nanodisks for Cancer Therapy.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- A DoE-Dual centrifugation-driven screening platform for liposomal incorporation of poorly soluble APIs: Application to the PROTAC ACBI2.International journal of pharmaceutics: X · 2026Article
- Synthesis of RARα-PROTAC and its delivery viaMaterials today. Bio · 2026Article
- In Situ Bioorthogonal Synthesis of PROTACs via Dual-Responsive Cleavage for Synergistic Photo-Immunotherapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Supramolecular Degraders: An Emerging Paradigm in Targeted Protein Degradation.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Delivering Degradation: Nanomedicine and Programmable Proximity Platforms for Targeted Protein Degradation.Pharmaceutics · 2026Review
- PROTAC-mediated regulation of programmed cell death: From molecular mechanisms to therapeutic breakthroughs.Innovation (Cambridge (Mass.)) · 2026Review
- The application of drug delivery systems based on targeted protein degradation chimeras in disease treatment strategies.Journal of nanobiotechnology · 2026Review
- Nano-PROTACs for precision medicine: engineering strategies for enhanced targeting and potency.Journal of nanobiotechnology · 2026Review
- Research progress and future perspectives in proteolysis-targeting chimeras.Frontiers in pharmacology · 2026Review
- Remodeling the Physicochemical and Pharmacokinetic Properties of PROTAC via Lipid Nanodisks for Cancer Therapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Proteolysis targeting chimera (PROTAC), as an emerging approach for target protein degradation based on the intracellular ubiquitin-protease system, is characterized by catalytic and reusability over traditional inhibitors. However, PROTACs are fraught with pharmacokinetic dangers due to poor water solubility and membrane permeability, further posing a huge challenge to the clinical potential. Herein, a nanodelivery system is developed that is elaborately decorated with prodrugs to improve the physicochemical properties and therapeutic efficacy of PROTAC. The nanodelivery, lipid nanodisk (LND), is readily assembled from three commercially available phospholipids, and shows high stability and long circulation time in vivo. The lipid-derived prodrug realizes prolonged retention and precise release of PROTACs at tumor sites under the endogenous stimulus. Collectively, the LND loaded with MZ1 prodrug (LND-MZ1) presents enhanced biocompatibility, improves intracellular accumulation, and superior tumor penetration capacity, enabling more potent and targeted PROTAC therapy with enhanced specificity in vivo. LND-MZ1 shows a more significant anti-tumor effect in the xenograft tumor model, even at a one-tenth dose of the parent PROTACs under the same therapeutic schedule. Overall, the LND-based nanomedicine paves the way for remodeling the physicochemical and pharmacokinetic properties of various drugs to expand the therapeutic scope.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.